Articles tagged "Efficacy"

2022 American Transplant Congress
Enhanced Delivery of Nanomedicine to Human Kidney During Ex Vivo Perfusion
C. Albert¹, L. Bracaglia¹, A. Koide², J. R. DiRito¹, T. Lysyy¹, E. Christopher¹, J. Grundler¹, J. T. Langford¹, D. Haakinson¹, J. S. Pober¹, W. M. Saltzman¹, S. Koide², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY
*Purpose: An efficient delivery of therapeutic agents to graft endothelial cells (ECs) prior to transplantation could render organs more resistant to injury, improving clinical outcomes…
2022 American Transplant Congress
Complement 5 Regulation Ameliorates Antibody-Mediated Rejection After Liver Transplantation in Rats
T. Tajima¹, K. Hata¹, J. Kusakabe¹, H. Miyauchi¹, X. Zhao¹, S. Kageyama¹, T. Okamoto¹, Y. Wang², E. Hatano¹
¹Dept. of HBP Surgery & Transplantation, Kyoto University, Kyoto, Japan, ²Alexion Pharmaceuticals Inc., New Haven, CT
*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible organ transplantation. Since AMR significantly deteriorates transplant outcomes, there is…
2022 American Transplant Congress
Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on Covid-19 Infection in Kidney Transplant Recipients
N. Sutharattanapong, S. Thotsiri, S. Kantachuvesiri, P. Wiwattanathum
Excellent Center of Organ Transplantation, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
*Purpose: Most developing countries do not have access to high-efficiency mRNA vaccine. In Thailand, the first and most available vaccines were inactivated, and later on,…
2022 American Transplant Congress
External Validation of the Abbreviated Ibox Scoring System at One-Year Post Kidney Transplant as a Surrogate Endpoint for Death-Censored Graft Survival
A. Klein¹, L. Kosinski², R. Muse², A. Loupy³, O. Aubert³, G. Divard³, M. Stegall⁴, I. Helanterä⁵, W. E. Fitzsimmons¹, I. O'Doherty¹
¹Transplant Therapeutics Consortium, Critical Path Institute, Tucson, AZ, ²Critical Path Institute, Tucson, AZ, ³Paris Transplant Group, Paris, France, ⁴Mayo Clinic, Rochester, MN, ⁵Helsinki University Hospital, Helsinki, Finland
*Purpose: The Transplant Therapeutics Consortium seeks to translate the iBox from Loupy et al., 2019 into a surrogate endpoint for five-year death-censored graft survival after…
2022 American Transplant Congress
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide (TAF) for HBV Prophylaxis
E. Gane¹, B. George¹, D. Ray-Chaudhuri¹, T. Mules¹, C. D. Holt², H. Wang², V. Suri², A. Gaggar², A. Osinusi², J. Flaherty²
¹Auckland City Hospital and University of Auckland, Auckland, New Zealand, ²Gilead Sciences, Inc., Foster City, CA
*Purpose: Recommended antiviral prophylaxis to prevent recurrent HBV infection after liver transplantation includes tenofovir disoproxil fumarate (TDF). However, given risks of bone/renal toxicity associated with…
2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2021 American Transplant Congress
Versatile Strategy to Enhance Nanomedicine Delivery to Graft Endothelial Cells
C. Albert¹, L. G. Bracaglia¹, A. Koide², J. DiRito¹, T. Lysyy¹, C. Edwards¹, J. T. Langford¹, D. Haakinson¹, S. A. Hosgood³, M. L. Nicholson³, J. S. Pober¹, W. M. Saltzman¹, S. Kiode², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University, Langone Medical Center, New York, NY, ³University of Cambridge, Cambridge, United Kingdom
*Purpose: Efficient delivery of therapeutics to graft endothelial cells (EC) can potentially render organs more resistant to injury, improving clinical outcomes. Specific targeting of polymeric…
2021 American Transplant Congress
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients
K. Fitton, A. Chan, C. Truax, B. Sirandas, T. Larson, L. Smith, A. Carlson
University of Utah Health, Salt Lake City, UT
*Purpose: Invasive fungal infection (IFI) after liver transplant (LT) is associated with significant morbidity and mortality. The optimal antifungal prophylaxis regimen has not been defined.…
2021 American Transplant Congress
Rabbit Anti-thymocyte Globulin Induction Dosing Strategies in a High-risk Kidney Transplant Population
C. Nguyen, R. Yau, C. Tunwar
Pharmacy, CHI Baylor St. Luke's Medical Center, Houston, TX
*Purpose: The objective of this retrospective observational study is to compare the safety and efficacy of two dosing strategies, rabbit anti-thymocyte globulin (rATG) at a…
2021 American Transplant Congress
Outcomes in Standard vs. Extended Use of Thymoglobulin as Induction Therapy in Kidney Transplant Recipients
N. M. Sifontis¹, A. Coleman¹, D. Tang¹, K. Lau², S. Karhadkar², A. DiCarlo², A. Diamond²
¹Temple University School of Pharmacy, Philadelphia, PA, ²Temple University Health System, Philadelphia, PA
*Purpose: Thymoglobulin induction along with modern maintenance immunosuppression has been found to have a significant reduction in acute rejection in kidney transplantation. The recommended duration…